They could also include other clinical manifestations now considered non-criteria such as nephropathy and cardiac valvulopathy in the ongoing classification criteria of TAPS and recommend the use of new laboratory tests such as anti-prothrombin-phosphatidylserine antibodies [39, 40]. This evidence concerns the gene F2 and Nephropathy.